BioMed Realty’s $720 Million sale of the Landmark at Eastview Property

Simpson Thacher is representing affiliates of BioMed Realty, L.P., in connection with its proposed sale of The Landmark at Eastview property to Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for $720 million, subject to customary prorations and adjustments.

Closing of this transaction is currently scheduled for the first quarter of 2017 and is subject to customary closing conditions.

The Landmark at Eastview property consists of approximately 150 acres of predominantly office buildings and laboratory space located in the towns of Mount Pleasant and Greenburgh, New York. The Firm represented Blackstone in connection with its acquisition of BioMed Realty Trust, Inc. for $8 billion in early 2016. BioMed Realty owns, acquires, develops, leases and manages laboratory and office space for life science tenants.

The Simpson Thacher team included Sas Mehrara (Picture), Davis Coen, Sarah Green, Aryeh Goldman and Natalie Winkelman (Real Estate); and Nancy Mehlman and Jodi Schneider (Tax).

Involved fees earner: Sasan Mehrara – Simpson Thacher & Bartlett; Davis Coen – Simpson Thacher & Bartlett; Sarah Green – Simpson Thacher & Bartlett; Aryeh Goldman – Simpson Thacher & Bartlett; Nancy Mehlman – Simpson Thacher & Bartlett; Jodi Schneider – Simpson Thacher & Bartlett;

Law Firms: Simpson Thacher & Bartlett;

Clients: BioMed Realty Trust;


Author: Ambrogio Visconti